SARM1 Inhibitors: A Novel Approach Against Neurodegenerative Di

  • Presently, several industry and non-industry stakeholders are evaluating SARM1 inhibitors as potential therapeutic agents for the treatment of neurological disorders across various preclinical studies and early stages of clinical development, worldwide.

     

    Given the encouraging research outcomes, the players in this domain have received more than USD 10 million in grants, since 2014, from the various private and public organizations.

    Additionally, several patents related to SARM1 targeting therapies have been recently filed / granted, demonstrating the continued innovation in this domain. Driven by the ongoing pace of innovation in this field, increasing R&D activity and promising pre-clinical data, several promising leads are anticipated to be commercially launched over the coming decade and SARM1 targeting therapeutics market is anticipated to witness substantial growth in the mid to long-term.

     

    Current Market Trend

    At present, several companies worldwide have taken initiatives to develop SARM1 inhibitors for targeting multiple neurological disorders, including multiple sclerosis and amyotrophic lateral sclerosis. The market is characterized by a mix of well-established and small firms. Currently, their pipeline features both biologics and small molecules drugs, which are being evaluated in preclinical and discovery stages.

     

    Strong Intellectual Property Portfolio

    Over the years, the number of patents filed for SARM1 inhibitors has increased gradually; majority of the patents have been filed / granted in 2021. In addition, most of the patents in this domain are patent applications (96%), followed by granted patents (3%).

     

    Future opportunities for SARM1 Inhibitors

    Currently, there are no potential treatment options that target axonal degeneration associated disorders. Across various studies, SARM1 inhibitors have demonstrated the potential to treat multiple neurodegenerative disorders; once approved, these therapies are likely to capture a sizeable market share in the coming future. Further, we expect the first product to be commercially launched in 2033; post that, the market is expected to grow at an annualized rate of 102%.

     

    For additional details, please visit 

    https://www.rootsanalysis.com/blog/sarm1-inhibitors-market/ or email sales@rootsanalysis.com

     

    You may also be interested in the following titles:

    1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
    2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035

    About Roots Analysis

    Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

                           

    Contact:

    Ben Johnson

    +1 (415) 800 3415
    Ben.johnson@rootsanalysis.com